PTPI Stock Price has plummeted, is it ready to bounce? URGENT
Petros Pharmaceuticals PTPI stock price is down –4% in the last 5 days & volume is up 7%, but is it over for this breakout stock?
In this in depth report, I look at 5 KPIs: Technical Analysis, Volume, News Cycle, Fundamentals & awareness campaigns.
Before we get started, I like being methodical and easy to understand so I have developed a ranking system for my stocks. I call it, Alexander Goldman’s “HOT Stock Ranking!”
The official heat level for PTPI is, a 🔥🔥2 out of 4
Before I get ahead of myself and just jump right into this exciting breakout stock, I wanted to introduce myself.
Hello 🙋♂️ My name is Alexander Goldman. I have been trading small cap stocks, breakout stocks and trending stocks for 20 years now. I established the coveted HOT Stock Reporting system.
To find out more about my story, CLICK HERE
[thrive_leads id=’28419′]
Petros Pharmaceuticals Company Information
Company Name: Petros Pharmaceuticals Inc
Ticker: PTPI
Exchange: NASDAQ
Website: https://www.petrospharma.com/
Petros Pharmaceuticals Company Summary:
Petros Pharmaceuticals, Inc. engages in men’s health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie’s disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.EBML stock price is due to News?
PTPI stock price is due to News?
- Announced the pursuit of the 505(b)(2) pathway for early stage asset, H-100 for the treatment of Peyronie’s Disease
- Initiated sponsored research agreement with Massachusetts General Hospital to evaluate incorporating the use of a tissue-specific oxygenation sensor with the goal of monitoring and understanding the success of Erectile Device Therapy.
- Reported positive results of a Phase 2 label comprehension study to initiate process for STENDRA(R) prescription erectile dysfunction medication to support the process for designation as over -the-counter treatment
- Engaged with celebrity physician, Dr. Drew Pinsky to provide patient education about erectile dysfunction and branded STENDRA messaging
- Announced an agreement with a leading U.S. based global contract manufacturer for STENDRA
Trending Stock PTPI 5 Day Chart
PTPI Stock Price HOT Stock Grade:
PTPI is, a 🔥🔥2 out of 4 . Here are my takeaways on it and why it is just a 3 out of 4.
PTPI Trading Volume
The volume, the normal trading volume is established by the previous 30 days of trading and this stock is trading at an increase of 7% over the average. Normally, this indicates a higher demand in the stock or a sell off (selling pressure).
Trading 101: volume is measured in the number of shares traded. Traders look to volume to determine liquidity and combine changes in volume with technical indicators to make trading decisions. So, let’s take a look at the technical indicators.
PTPI Technicals
The technical analysis “chart reading”, this stock is down -3% on the 5 day chart and the overall trend for the long term chart, the 1 month, is down -31%. We are still waiting for the bottom. I imagine good news should be coming soon, pay attention and bookmark it.
Trading 101: Technical indicators are technical tools that help in analyzing the movement in the stock prices whether the ongoing trend is going to continue or reverse. It helps the traders to make entry and exit decisions of a particular stock. Technical indicators can be leading or lagging indicators.
PTPI News Cycle
The news, there is no significant news.
PTPI Fundamentals
The fundamentals, how a company is doing financially can be a serious KPI and there is no exciting financial filings associated with this stock.
Trading 101: Fundamental trading is a method where a trader focuses on company-specific events to determine which stock to buy and when to buy it. Trading on fundamentals is more closely associated with a buy-and-hold strategy rather than short-term trading.
PTPI Awareness
Marketing efforts “Awareness Campaigns” Just like advertising a prroduct is important, advertising a publicly traded company during a news cycle is critical for the stock price of a company.
I have found marketing efforts around the investor awareness of this company. So, I have awarded this stock a 2 out of 4. Do you agree? Write me a line at [email protected]
Again, two heads are better than one, let’s work together to have the best trading year of our lives!
To receive my 🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter, sign up today.
To find out more about my story, CLICK HERE
👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥 HOT stocks and we can compare notes!👇
[thrive_leads id=’28419′]
Petros PTPI bounce play alert–
Petros PTPI is possibly about to explode again as the short position increases as PPS is ticking up. Pay attention to PTPI as this stock may skyrocket
Petros Pharma PTPI company summary
Company Name: Petros Pharmaceuticals, Inc.
Ticker: (PTPI)
Exchange: NASDAQ
Website: https://www.petrospharma.com/
Petros PTPI Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.
Why is it down?
The NEWS:
Petros PTPI released incredible news that is found below late in 2021.
Petros reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use.
What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?
PTPI 5 Day Chart
PTPI 5 Day Analysis
This stock is fully consolidated so I expect the moment they issue positive news, it will skyrocket.
PTPI 1 Day Chart
1 Day Analysis
You can clearly see thin the one day that there is a slight bearish trend. Get ready traders because I’ve been following PTPI for a while and I believe it is getting ready for another move as long as the stock has good news attached to it to get it going.
Petros Pharmaceuticals PTPI short squeeze
Petros Pharmaceuticals PTPI is possibly about to explode again as the short position increases as PPS is ticking up. Pay attention to PTPI as this stock may skyrocket
Petros PTPI company summary
Company Name: Petros Pharmaceuticals, Inc.
Ticker: (PTPI)
Exchange: NASDAQ
Short Squeeze Article: HERE
Petros PTPI Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.
Why is it red HOT?
The NEWS:
Petros reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use.
What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?
The Short Squeeze
Look HERE at our buddies over at Fintel.io. This stock has a big short position and could go crazy!
PTPI 5 Day Chart
PTPI 5 Day Analysis
The convergence point is coming Traders! All signs are pointing to a short squeeze! It is coming late Friday or Monday! Once PTPI breaks $2.82 & $2.90, boom like a rocket ship!
PTPI 1 Day Chart
1 Day Analysis
You can clearly see the $2.82 resistance. Get ready traders because I’ve been following PTPI for a while and I can hear the juice machine warming up for the BIG squeeze.
UPDATE:! 100% Correct, Alex made 5 correct predictions for Petros Pharmaceuticals, Inc. PTPI!
Company Name: Petros Pharmaceuticals, Inc.
Ticker: (PTPI)
Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.
Why is it red HOT?
Petros reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use.
What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?
Alex wrote on Monday 12/13/21 a 5 Day Technical Analysis based on this chart below:
The Predictions
“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s take a close look at the 1 day.” “It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?”
Let’s look at each prediction
Prediction #1 “about to go bearish”
“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish “It’s very simple, can it beat $4.38? If it can’t, I would expect a pullback then consolidation and then a run!
Let’s look at where it is around lunch on Wednesday 12/15/21
WOW Alex called prediction 1 with a 38% pullback
Prediction #2 “I would expect a pullback then consolidation”
“If it can’t, I would expect a pullback then consolidation and then a run!” You can see in the above chart the consolidation call! This is not fortune telling, the chart is like a book and if you know how to read the language it is written in, it makes total sense!
As you can see from the above chart it most definitely consolidated. Let’s see what happened after consolidation!
Alex Goldman Prediction #3: “RUN“
“I would expect a pullback then consolidation and then a run!“
As you can see from the above chart it ran MINUTES after the article was finished and gave our subscribers a chance at 28% & 43% RUNS.
Alex Goldman Prediction #4: “It is about to run”
Alex wrote a follow up Article HERE Wednesday last week Dated 12/15/21 updating our subscribers
Alex wrote on midday Wednesday 12/15 “It is about to run! It is bullish and I like it! Put it on your watchlist and Let’s make some money!!!!”
Alex Goldman Prediction #5: “SCALP”
“wait for confirmation of a reversal and get ready for a quick scalp.“
Alerted our EXCLUSIVE subscribers via email yesterday 12/20/21.
You can sign up below
Alex wrote in the email on Monday 12/20 “It is now in a bearish trend for the 1 day but still bullish overall. My recommendation is to wait for confirmation of a reversal and get ready for a quick scalp.”
SCREENSHOT PROOF FROM OUR EMAIL HERE
OK it is official, Alex really really knows the movement and nuances of this chart! He called yet another massive gain today at 49%
What is Alex’s next prediction for PTPI?
Sign up for our newsletter below, IT’S FREE and you could win $250!
UPDATE: Alex believes Petros Pharma (PTPI) is ready to BOUNCE, PAY ATTENTION!
Company Name: Petros Pharmaceuticals, Inc.
Ticker: (PTPI)
Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.
Why did it go up over 100%?
reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.
“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?
I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.
I wrote on Monday 12/13/21 a 5 Day Technical Analysis:
“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s take a close look at the 1 day.”
Yes, I was right it went BEARISH!
I wrote on Monday 12/13/21 a 1 Day Technical Analysis:
“It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?”
Let’s look at where it is around lunch on Wednesday 12/15/21
WOW I called it, it didn’t break $4.38 and it did PULLBACK 38%!
Called it AGAIN, Now it is consolidating!
Alex Goldman Prediction:
It is about to run! It is bullish and I like it! Put it on your watchlist and Let’s make some money!!!!
Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?
Company Name: Petros Pharmaceuticals, Inc.
Ticker: (PTPI)
Exchange: NASDAQ
Website: https://STENDRA.com/.
Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.
Why did it go up over 100%?
Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today reports positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.
“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the United States. While the process of gathering data to be shared with the U.S. Food and Drug Administration (FDA) continues, we are enthusiastic about our progress toward providing new hope for the millions of men suffering from this condition,” commented Fady Boctor, Petros’s President and Chief Commercial Officer.
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?
I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.
5 Day Technical Analysis:
It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s tak a close look at the 1 day.
1 Day CHart Technical Analysis
It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?
Winners and Losers: PTPI, MTTR, and NRXP
Company Name: Petros Pharmaceuticals, Inc.
Ticker: PTPI
Exchange: NASDAQ
Website: https://www.petrospharma.com/
Industry: Health & Wellness
Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health and substance use disorders.
Why is it so Bullish?
Nov. 30, 2021 Petros Pharmaceuticals announces that it has entered into definitive agreements with the company’s largest investor and other existing investors, for the purchase and sale of 3,333,333 shares of Petros Pharmaceuticals’ common stock, at a purchase price of $3.00 per share. The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement. Petros Pharmaceuticals has also agreed to issue the investors unregistered warrants to acquire 2,500,000 shares of common stock at an exercise price of $3.50 per share, exercisable immediately and terminating 5 years after the date of issuance. The closing of the offering is expected to occur on or about December 2, 2021, subject to the satisfaction of customary closing conditions.
1 Day Chart
Technical Summary
Based on the 5 day chart and 1 day chart, I would consider this a bearish trend and would AGAIN, wait for confirmations of a reversal before considering a purchase. NOTE, the 1 month looks interesting but again the short term charts are bearish.
—————————————————————————————————–
Company Name: Matterport, Inc.
Ticker: (MTTR)
Exchange: NASDAQ
Website: https://matterport.com/
Industry: Tech
Company Summary:
Matterport, Inc. (Nasdaq: MTTR) is leading the digital transformation of the built world. Our groundbreaking spatial data platform turns buildings into data to make nearly every space more valuable and accessible. Millions of buildings in more than 150 countries have been transformed into immersive Matterport digital twins to improve every part of the building lifecycle from planning, construction, and operations to documentation, appraisal and marketing.
Why is it so Bullish?
On Nov. 23, 2021 Matterport announced another expansion of Matterport Capture Services™ On-Demand that adds 16 U.S. cities and 20 in Great Britain to its service map, increasing its regional coverage by 55 percent.
5 Day Chart
Technical Summary
Love this stock, it is very bullish and has great news announced today, see below.
Nov. 30, 2021, Matterport introduced Matterport BIM file, a new add-on service that dramatically decreases the time and costs of Building Information Modeling (BIM) for the Architecture, Engineering, and Construction (AEC) industry. Now included with a Matterport subscription, customers can quickly transform a Matterport digital twin captured by a compatible 3D camera into a ready-to-use BIM file at the click of a button. The output is delivered in days, ready to be brought into their BIM application of choice. This new service significantly expedites projects and reduces associated costs by up to 70%, eliminating the traditional manual process that requires considerable time and effort.
—————————————————————————————————–
Company Name: NRx Pharmaceuticals, Inc.
Ticker: (NRXP)
Exchange: NASDAQ
Website: www.nrxpharma.com
Industry: Medical
Company Summary:
NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. The Company is developing the BriLife® Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense. NRx is additionally developing ZYESAMI® (aviptadil) for patients with COVID-19, and has been granted Fast Track designation by the US Food and Drug Administration (FDA), and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022.
Why is it so Bullish?
Nov. 29, 2021 NRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.
1 Day Chart
Technical Summary:
Another Covid stock, another overbought play that could be a winner but we need confirmation and understanding that it will be volatile.